Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. Approximately 676 eligible subjects with intermediate- or poor-risk advanced or metastatic RCC by IMDC criteria will be randomized in a 1:1 ratio (~338 per treatment arm) at approximately 150 sites.
Not Available
III
Beckermann, Kathryn
NCT03937219
VICCURO1938

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: